References
- American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society, 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf [Last accessed 6 January 2015]
- Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, version 1.2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [Last accessed 6 January 2015]
- Hartman JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81
- Coppin C. Sunitinib for advanced renal cell cancer. Biologics 2008;2:97-105
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
- Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
- Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
- Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31
- Sun M, Larcher A, Karakiewicz P. Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis 2014;29:401-7
- Delea T, Amdahl J, Diaz J, et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm 2015;21:46-54
- Hansen R, Hackshaw M, Nagar S, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015;21:37-44
- Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 2006;12:110-19
- Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84-99
- Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care 2003;41:753-60
- Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003;41:761-4
- Gore ME, Bellmunt J, Eisen T, et al. Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). Eur J Cancer 2014;50:3153-60
- Haaland B, Chopra A, Acharyya S, et al. Comparative effectiveness of first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer 2014;14:592-601
- Hackshaw M, Nagar S, Parks D, Miller L. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm 2014;20:603-10
- Byfield S, McPheeters J, Burton T, et al. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. J Manag Care Spec Pharm 2015;21:515-22
- Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36